Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results
The pharmaceutical giant released fresh trial data showing the drug helped obese or overweight type 2 diabetics lose an ...
Ozempic parent’s new weight-loss drug works better, but not quite good enough
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Hosted on MSN3m
Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug
Last week, Novo Nordisk launched an online pharmacy, Novocare, to allow consumers to purchase Wegovy directly from the ...
5 things to know before the stock market opens Monday
Stock futures fell again Monday, after the S&P 500 had its worst week in months amid fears about President Donald Trump's tariff policy. Mark Carney won the race to replace Justin Trudeau as Canada's ...
Le Lézard59m
U.S. Medical Weight Loss Market Report 2025: The Impact of GLP-1s on Doctors, Hospitals, Clinics and Franchises - ResearchAndMarkets.com
The "U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering. This report presents a complete picture of the medical weight loss market in the ...